Live Breaking News & Updates on Cancer Symposium

Stay updated with breaking news from Cancer symposium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC

Triplet therapy consisting of encorafenib, cetuximab, and binimetinib demonstrated activity and manageable safety as first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer. ....

Van Cutsem , Dimension Or European Organization For Research , Cancer Symposium , Level Euroqol , European Organization , Cancer Qol Questionnaire Core , Patient Global Impression , Braf V600e Mutated Metastatic Colorectal Cancer , Braf V600e ,

Dr Kopetz on the Rationale of the BREAKWATER Study in BRAF V600Emutant mCRC

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E–mutant metastatic colorectal cancer.
....

United States , Scott Kopetz , Division Of Cancer Medicine , Department Of Gastrointestinal Medical Oncology , University Of Texas Md Anderson Cancer Center , Gastrointestinal Medical Oncology , Cancer Medicine , Cancer Center , Cancer Symposium , The University Of Texas Md Anderson Cancer Cente , Onclive Tv , Colorectal Cancer ,

Quarterly Business Update – March 2023

Quarterly Business Update – March 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , San Francisco , New York , Simon Morriss , Adrian Mulcahy Automic , Test Panel Expanded To , American Society Of Clinical Oncology Gastroenterology , Board Of Genetic Technologies , Genetic Technologies Ltd , Genetic Technologies Limited , Strategic Alliance , Centre Of Excellence , Genetic Technologies , Exchange Commission , Technologies Limited , Comprehensive Breast , Ovarian Cancer Risk Test , Chief Executive Officer Simon Morriss , Medical Science Liaison , Key Opinion Leader , Achievements During , Quartergenetype Commercial Progress , Budget Impact Model , Type Multi Test Panel Expanded , Pancreatic Cancer , First Comprehensive Breast ,

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage. ....

United States , San Francisco , Development Expenses , Regulation Services Provider , American Urology Association , Company Anti , American Society Of Clinical Oncology , Toronto Stock Exchange Venture , Life Sciences , Technologies Inc , Venture Exchange , Company Photo Dynamic Compounds , Clean Technology , Photo Dynamic Compounds , Consolidated Statements , Canadian Dollars , Muscle Invasive Bladder Cancer , Anti Cancer Therapy , Diversified Industries , Non Brokered Private , Trade Name , Break Through Designation , Study Treatment , Principal Investigator , Evaluable Patients , Indeterminate Response ,

Theralase® Releases FY2022 Audited Financial Statements

Theralase® Releases FY2022 Audited Financial Statements
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San Francisco , United States , Development Expenses , Regulation Services Provider , Technologies Inc Theralase , American Urology Association , Life Sciences , Technologies Inc , American Society Of Clinical Oncology , Company Anti , Toronto Stock Exchange Venture , Clean Technology , Company Photo Dynamic Compounds , Venture Exchange , Theralase Technologies Inc , Photo Dynamic Compounds , Consolidated Statements , Canadian Dollars , Muscle Invasive Bladder Cancer , Anti Cancer Therapy , Diversified Industries , Non Brokered Private Placementson September , Trade Name , Break Through Designation , Study Treatment , Principal Investigator ,